Conference Call Schedules, Presentations, Collaborations and FDA Approvals - Research Report on Pharmacyclics, Pacira

 Conference Call Schedules, Presentations, Collaborations and FDA Approvals -
       Research Report on Pharmacyclics, Pacira Pharmaceuticals, Raptor
               Pharmaceuticals, Impax Laboratories, and AcelRx

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 6, 2013

NEW YORK, November 6, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting
Pharmacyclics Inc. (NASDAQ: PCYC), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX),
Raptor Pharmaceuticals Corp. (NASDAQ: RPTP), Impax Laboratories Inc. (NASDAQ:
IPXL), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Pharmacyclics Inc. Research Report

On November 1, 2013, Pharmacyclics Inc. (Pharmacyclics) announced that it will
host a conference call and audio webcast on Thursday, November 7, 2013, at
4:30 p.m. ET, to discuss its Q3 2013 financial results and recent
developments. According to the Company, a replay of the webcast will also be
available on Pharmacyclics' website for 30 days. The Full Research Report on
Pharmacyclics Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/df74_PCYC]

--

Pacira Pharmaceuticals Inc. Research Report

On November 1, 2013, Pacira Pharmaceuticals Inc. (Pacira Pharmaceuticals)
announced that its President, CEO and Chairman, Dave Stack will present an
overview of the Company at two investor conferences during November 2013.
Pacira Pharmaceuticals informed that Mr. Stack's presentation at the Goldman
Sachs US Emerging / SMID Cap Growth Conference is scheduled on Thursday,
November 14, 2013, at 2:40 p.m. ET in New York. Meanwhile, Mr. Stack will also
present the Company at the Jefferies 2013 Global Healthcare Conference on
Thursday, November 21, 2013, at 9:20 a.m. BST or 4:20 a.m. ET in London, UK.
According to the Company, a live audio webcast of the aforementioned
presentations can be accessed through the investor & media section at Pacira
Pharmaceuticals' website. The Full Research Report on Pacira Pharmaceuticals
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/c0aa_PCRX]

--

Raptor Pharmaceuticals Corp. Research Report

On October 23, 2013, Raptor Pharmaceuticals Corp. (Raptor Pharmaceuticals)
announced that it has collaborated with DaVita Clinical Research® (DCR) to
screen blood samples from patients with end-stage renal disease (ESRD) in an
effort to identify patients with unrecognized late-onset nephropathic
cystinosis. According to the Company, DCR will supply blood samples with
clinical data annotation from its biorepository of over four thousand patients
with ESRD. Commenting on the new collaboration, Raptor Pharmaceuticals' CEO,
Christopher M. Starr, Ph. D. stated, "Today, most nephropathic cystinosis
patients are identified in infancy by pediatric nephrologists, yet, as with
many genetic diseases, later-onset patients have been identified where the
clinical manifestations of cystinosis may go unrecognized well into adulthood.
We believe these late-onset patients are likely to present with ESRD as adults
and this screening program, initiated with this collaboration, may help adult
nephrologists, many of whom are unfamiliar with the late onset form of the
disease, identify patients who suffer from cystinosis." The Full Research
Report on Raptor Pharmaceuticals Corp. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.analystscorner.com/r/full_research_report/a001_RPTP]

--

Impax Laboratories Inc. Research Report 

On October 30, 2013, Impax Laboratories Inc. (Impax Laboratories) and TOLMAR,
Inc. jointly announced the receipt of final FDA approval for Generic Solaraze®
Gel. According to the Company, the US Food and Drug Administration (FDA) has
granted final approval of TOLMAR's Abbreviated New Drug Application (ANDA) for
its generic version of Solaraze® Gel (diclofenac sodium - 3%). The two
companies further informed that TOLMAR was the first company to file a
substantially complete ANDA containing a Paragraph IV certification, and
Impax's generics division, Global Pharmaceuticals, intends to commercialize
this first-to-file product shortly. According to Impax Laboratories, under a
Development, Supply, and Distribution Agreement between the duos, TOLMAR, Inc.
granted the Company an exclusive license to commercialize generic Solaraze in
the US and its territories, while the former was responsible for developing
and manufacturing the product. The Full Research Report on Impax Laboratories
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/4c54_IPXL]

--

AcelRx Pharmaceuticals, Inc. Research Report

On October 15, 2013, AcelRx Pharmaceuticals, Inc. (AcelRx) announced the
presentations of its previously reported Phase 3 data for Zalviso™ (sufentanil
sublingual microtablet system) at several major medical meetings in Europe and
the US. According to the Company, AcelRx presented data from the Phase 3
clinical trial conducted in orthopedic surgery patients at the European
Federation of IASP Chapters (EFIC) Annual Congress from October 9 - 12, 2013,
in Florence, Italy and at the American Society of Anesthesiologists (ASA)
meeting from October 12 - 16, 2013, in San Francisco. Richard King, President
and CEO of AcelRx commented, "Presentations at important medical meetings in
both the EU and US of favorable Phase 3 data for Zalviso represent an
opportunity for investigators to discuss the trials and their impressions of
Zalviso with other thought leaders in the pain-treatment community.
Presentations of this data are an important step in the familiarization of the
medical community with Zalviso, and in enabling early understanding of the
potential value the product may provide to their patients, if approved by the
regulatory agencies." The Full Research Report on AcelRx Pharmaceuticals, Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/1454_ACRX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)